These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 24955573

  • 21. Stroke prevention in atrial fibrillation: established oral anticoagulants versus novel anticoagulants-translating clinical trial data into practice.
    Ezekowitz MD, Spahr J, Ghosh P, Corelli K.
    J Interv Card Electrophysiol; 2014 Sep; 40(3):261-8. PubMed ID: 24880227
    [Abstract] [Full Text] [Related]

  • 22. Direct oral anticoagulants in atrial fibrillation.
    Noll G, Noll S, Hürlimann D.
    Semin Hematol; 2014 Apr; 51(2):139-46. PubMed ID: 24861798
    [Abstract] [Full Text] [Related]

  • 23. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR, Zhou L, Gellad WF, Lee JK, Slack MK, Martin JR, Lo-Ciganic WH.
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [Abstract] [Full Text] [Related]

  • 24. New oral anticoagulant agents - general features and outcomes in subsets of patients.
    Schulman S.
    Thromb Haemost; 2014 Apr 01; 111(4):575-82. PubMed ID: 24452881
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
    Assiri A, Al-Majzoub O, Kanaan AO, Donovan JL, Silva M.
    Clin Ther; 2013 Jul 01; 35(7):967-984.e2. PubMed ID: 23870607
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Steinberg BA, Shrader P, Thomas L, Ansell J, Fonarow GC, Gersh BJ, Hylek E, Kowey PR, Mahaffey KW, O'Brien EC, Singer DE, Peterson ED, Piccini JP, Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators and Patients.
    Am Heart J; 2017 Jul 01; 189():40-47. PubMed ID: 28625380
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C.
    Int Angiol; 2012 Aug 01; 31(4):330-9. PubMed ID: 22801398
    [Abstract] [Full Text] [Related]

  • 32. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
    Hohnloser SH, Camm J, Cappato R, Diener HC, Heidbuchel H, Lanz HJ, Mont L, Morillo CA, Smolnik R, Yin OQP, Kautzner J.
    Clin Cardiol; 2018 Apr 01; 41(4):440-449. PubMed ID: 29663464
    [Abstract] [Full Text] [Related]

  • 33. Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results.
    Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Moia M, Palareti G, Poli D, Testa S, Tiraferri E, Tosetto A, Tripodi A, Siragusa S, Manotti C.
    J Thromb Haemost; 2012 Oct 01; 10(10):1979-87. PubMed ID: 22827490
    [Abstract] [Full Text] [Related]

  • 34. Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: A network meta-analysis with the adjustment for the possible bias from open label studies.
    Morimoto T, Crawford B, Wada K, Ueda S.
    J Cardiol; 2015 Dec 01; 66(6):466-74. PubMed ID: 26162944
    [Abstract] [Full Text] [Related]

  • 35. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
    Banerjee A, Lane DA, Torp-Pedersen C, Lip GY.
    Thromb Haemost; 2012 Mar 01; 107(3):584-9. PubMed ID: 22186961
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Comparative Clinical Outcomes of Edoxaban in Adults With Nonvalvular Atrial Fibrillation.
    Aronow WS, Shamliyan TA.
    Am J Ther; 2020 Mar 01; 27(3):e270-e285. PubMed ID: 30277905
    [Abstract] [Full Text] [Related]

  • 38. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S, Ansell J.
    Thromb Haemost; 2012 Sep 01; 108(3):476-84. PubMed ID: 22740145
    [Abstract] [Full Text] [Related]

  • 39. Evolving use of new oral anticoagulants for treatment of venous thromboembolism.
    Yeh CH, Gross PL, Weitz JI.
    Blood; 2014 Aug 14; 124(7):1020-8. PubMed ID: 24923298
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.